We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.58 | -21.56133829 | 2.69 | 2.73 | 1.83 | 98561 | 2.14109306 | CS |
4 | -1.2 | -36.253776435 | 3.31 | 3.49 | 1.83 | 53360 | 2.71746689 | CS |
12 | -1.98 | -48.4107579462 | 4.09 | 5.95 | 1.83 | 60721 | 3.75539251 | CS |
26 | -2.6899 | -56.040750849 | 4.7999 | 5.95 | 1.83 | 45410 | 3.65954821 | CS |
52 | -2.26 | -51.7162471396 | 4.37 | 5.99 | 1.83 | 32612 | 3.90476568 | CS |
156 | -3.297 | -60.976511929 | 5.407 | 9.6799 | 0.6706 | 363646 | 4.04658504 | CS |
260 | -29.09 | -93.2371794872 | 31.2 | 37.7 | 0.6706 | 591883 | 15.66648806 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions